News | Drug-Eluting Balloons | January 12, 2023

MedAlliance Selution SLR is the First DEB to Receive Coronary de novo IDE Approval, its Fourth FDA IDE DEB Approval

SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

January 12, 2023 — Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications; as well as occlusive disease of the superficial femoral artery (SFA); and coronary In-Stent Restenosis (ISR).

Enrollment of the Selution SLR coronary de novo  study will begin in the US within the next few months.

This will complement the substantial experience that the company has already gained with the Selution DeNOVO trial in Europe (ClinicalTrials.gov Identifier: NCT04859985).  More than 800 patients of the 3,326 planned have been enrolled in this ground-breaking coronary randomized controlled study comparing Selution SLR vs. any limus drug-eluting stent (DES). The study is powered to demonstrate superiority of Selution SLR drug-eluting balloon (DEB) over DES in coronary de novo artery disease.  This is the largest DEB study ever initiated and has the potential to change medical practice where implants (metal stents) have been the standard of care for more than 30 years.

"Treatment of de novo coronary arteries with drug-eluting balloons is a breakthrough in revascularization of coronary artery disease. The Selution SLR coronary de novo study is the first of its kind in the USA and will provide important data on the efficacy and safety of sirolimus- eluting balloon as a viable alternative to drug-eluting stent, leaving nothing behind post-PCI and eliminating in-stent restenosis and related complications" said Dr. Ron Waksman,  Professor of Cardiology at Georgetown University, Director of Cardiovascular Research at MedStar Heart and Vascular Institute, Washington DC  and Chairman of the MedAlliance Coronary Study Steering Committee.

“Coronary de novo lesions are the largest potential opportunity for use of DEB’S: the data has shown clearly that DES don’t work well in small vessels, long, or bi-furcated  lesions or in patients with diabetes or risk of high bleeding complications. These patients represent 60% of all patients currently treated with DES, who may now benefit from this exciting new DEB technology” added Jeffrey B. Jump, Chairman and CEO of MedAlliance.

Selution SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.

MedAlliance’s unique DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the anti-restenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days.

Selution SLR 014 PTCA is commercially available in Europe, Asia, the Middle East and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 10,000 coronary units have already been used for patient treatment in routine clinical practice or as part of clinical trials.

For more information: https://medalliance.com/

Related content:

First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval

MedAlliance’s SELUTION SLR Drug-eluting Balloon Receives FDA Investigational Device Exemption Approval


Related Content

News | Drug-Eluting Balloons

March 14, 2023 —MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo ...

Home March 14, 2023
Home
News | Drug-Eluting Balloons

January 27, 2023 — The first US patient has been enrolled at Medstar Washington Hospital Center in the SELUTION4ISR ...

Home January 27, 2023
Home
News | Drug-Eluting Balloons

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the Stellarex 0.035” OTW Drug-coated ...

Home January 02, 2023
Home
News | Drug-Eluting Balloons

November 28, 2022 – BIOTRONIK announced the presentation of one-year results from the investigator-initiatedBIOPACT RCT ...

Home November 28, 2022
Home
News | Drug-Eluting Balloons

October 28, 2022 — SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device ...

Home October 28, 2022
Home
News | Drug-Eluting Balloons

October 18, 2022 — Swiss-based medical technology company MedAlliance has announced it has entered into an agreement ...

Home October 18, 2022
Home
News | Drug-Eluting Balloons

August 23, 2022 — The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial ...

Home August 23, 2022
Home
News | Drug-Eluting Balloons

July 12, 2022 — Biotronik announced the presentation of two studies on the performance of its drug-coated balloon ...

Home July 12, 2022
Home
News | Drug-Eluting Balloons

June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial ...

Home June 08, 2022
Home
News | Drug-Eluting Balloons

May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 ...

Home May 27, 2022
Home
Subscribe Now